These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 6192987)

  • 1. [Chemotherapy in pretreated Hodgkin's disease with lomustine, bleomycin, vinblastine and dexamethasone].
    Weiss J; von Roemeling R; Peters HD; Schmoll HJ; Diehl V
    Dtsch Med Wochenschr; 1983 Sep; 108(38):1428-32. PubMed ID: 6192987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
    Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
    Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
    Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
    J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Recurrence of Hodgkin's disease after advanced primary stages. German Hodgkin's Study Group].
    Fuchs R; Löffler M; Pfreundschuh M; Dölken G; Gerhartz H; Hagen-Aukamp U; Hiller E; Petsch S; Pflüger KH; Rühl U
    Med Klin (Munich); 1992 Nov; 87(11):555-62. PubMed ID: 1281905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of two non-cross-resistant combinations (ABVP/LOPP) with COPP plus bleomycin in the treatment of advanced Hodgkin's disease.
    Koza I; Bohunický L; Mociková K; Gyárfás J; Svancárová L; Mardiak J; Spánik S; Fuchsberger P; Thalmeinerová Z; Sufliarsky J
    Neoplasma; 1991; 38(6):583-93. PubMed ID: 1722564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pediatric Hodgkin's disease.
    Oliapuram Jose B; Koerner P; Bertolone S; Patel CC; Spanos WJ; Paris KJ; Silverman CL; Yashar CM
    J Ky Med Assoc; 2004 Mar; 102(3):104-6. PubMed ID: 15067795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results.
    Bonadonna G; Santoro A; Bonfante V; Valagussa P
    Cancer Treat Rep; 1982 Apr; 66(4):881-7. PubMed ID: 6176323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can MOPP be replaced in the treatment of advanced Hodgkin's disease?
    Canellos GP
    Semin Oncol; 1990 Feb; 17(1 Suppl 2):2-6. PubMed ID: 1689509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
    Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
    J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of pediatric Hodgkin's disease with chemotherapy alone or combined modality therapy.
    Muwakkit S; Geara F; Nabbout B; Farah RA; Shabb NS; Hajjar T; Khogali M
    Radiat Oncol Investig; 1999; 7(6):365-73. PubMed ID: 10644060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
    Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R
    Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
    Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
    J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
    Al-Ali HK; Wittekind C; Niederwieser D
    Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The management of Hodgkin's disease with chemotherapy or combined modality treatment].
    Tsushita K; Utsumi M; Shimoyama M
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2202-9. PubMed ID: 9881076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
    Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
    Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
    Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP
    Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Early results of the treatment of Hodgkin's disease with alternating use in the CVPP and ABVD protocol].
    Gabryś K; Kotlarek-Haus S; Sciborski R
    Pol Tyg Lek; 1986 Feb; 41(7):195-8. PubMed ID: 2423994
    [No Abstract]   [Full Text] [Related]  

  • 19. CAV chemotherapy (CCNU, melphalan, etoposide) as salvage treatment for relapsing or resistant Hodgkin's disease.
    Brusamolino E; Castelli G; Pagnucco G; Orlandi E; Malagó D; Lazzarino M; Bernasconi C
    Haematologica; 1990; 75(4):340-5. PubMed ID: 1703510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
    Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F
    Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.